Clinical trial
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
NCT00400153 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00400153 |
|---|---|
| Title | Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes |
| Enrollment | 1,480 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2008 |
| First posted | Nov 16, 2006 |
| Last update posted | Jun 13, 2014 |
| Countries | Argentina, France, Greece, New Zealand, Poland, Russia, South Africa, South Korea, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: